Lenvima (Lenvatinib) belongs to the group of anti-cancer drugs, has anti-angiogenic properties that nourish cancer cells and directly inhibit tumor growth. This medicinal product was first approved by the US Food and Drug Administration (FDA) in 2015 with two strengths of 4mg and 10mg. Currently, the drug is available at Vinmec Times City with the concentration of lenvima 4mg.